54820-92-7

Basic information

• Product Name: 5-AMINO-1,3-DIMETHYL-1H-PYRAZOLE-4-CARBONITRILE
• Synonyms: 5-AMINO-1,3-DIMETHYL-1H-PYRAZOLE-4-CARBONITRILE;5-amino-1,3-dimethyl-4-pyrazolecarbonitrile;5-amino-1,3-dimethyl-pyrazole-4-carbonitrile;5-AMINO-1,3-DIMETHYLPYRAZOLE-4-CARBONITRILE
• CAS NO: 54820-92-7
• Molecular Formula: C₆H₈N₄
• Molecular Weight: 136.15
• Product Categories: Pyrazole series
• Mol File: 54820-92-7.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 327.3 °C at 760 mmHg
• Flash Point: 151.7 °C
• Appearance: /
• Density: 1.26 g/cm³
• CAS DataBase Reference: 5-AMINO-1,3-DIMETHYL-1H-PYRAZOLE-4-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-AMINO-1,3-DIMETHYL-1H-PYRAZOLE-4-CARBONITRILE(54820-92-7)
• EPA Substance Registry System: 5-AMINO-1,3-DIMETHYL-1H-PYRAZOLE-4-CARBONITRILE(54820-92-7)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• HazardClass: IRRITANT
• Hazardous Substances Data: 54820-92-7(Hazardous Substances Data)

Usage

General Description

5-AMINO-1,3-DIMETHYL-1H-PYRAZOLE-4-CARBONITRILE is a chemical compound with the molecular formula C6H8N4. It is a pyrazole derivative with an amino group and a carbonitrile group attached to the pyrazole ring. 5-AMINO-1,3-DIMETHYL-1H-PYRAZOLE-4-CARBONITRILE may have potential applications in the pharmaceutical or agrochemical industries due to its structural features and potential biological activities. Further research and investigation are necessary to fully understand the properties and uses of 5-AMINO-1,3-DIMETHYL-1H-PYRAZOLE-4-CARBONITRILE and its derivatives.

Upstream product

• 60-34-4 methylhydrazine 
• 5417-82-3 (1-ethoxyethylidene)malononitrile 
• 89943-20-4 2-cyano-3-ethoxythiocrotonamide 
• 5515-16-2 2-(methoxyethylidene)propanedinitrile 
• 7339-53-9 methyl hydrazine hydrochloride 
• 1187-11-7 acetylmalonodinitrile 

Downstream Products

• 1026602-36-7 N-(4-Cyano-2,5-dimethyl-2H-pyrazol-3-yl)-2-propoxy-benzamide 
• 1607479-48-0 C₂₂H₂₅N₉O 
• 1030377-75-3 1,3-dimethyl-6-{(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl}-1H-pyrazolo[3,4-d]pyrimidine 
• 5346-58-7 4-amino-1,3-dimethyl-1H-pyrazolo<3,4-d>pyrimidine 
• 1072895-86-3 4,6-dichloro-1,3-dimethyl-1H-pyrazolo[3,4-d]pyrimidine 
• 773140-12-8 N-(4-cyano-2,5-dimethyl-2H-pyrazol-3-yl)-2-fluoro-benzamide 
• 168464-48-0 C₁₉H₂₁N₇O₂S 

Relevant articles and documents

The pyrazole derivative or its salt in a pharmaceutical composition containing them

PROBLEM TO BE SOLVED: To provide a novel compound and a pharmaceutical composition useful for treatment and/or prevention of HIV virus infections.SOLUTION: Provided is a pyrazole derivative represented by the general formula (I) or a salt thereof (in the

1,3-disubstituted-4-aminopyrazolo [3, 4-d] pyrimidines, a new class of potent inhibitors for phospholipase D

Phospholipase D enzymes cleave lipid substrates to produce phosphatidic acid, an important precursor for many essential cellular molecules. Phospholipase D is a target to modulate cancer-cell invasiveness. This study reports synthesis of a new class of phospholipase D inhibitors based on 1,3-disubstituted-4-amino-pyrazolopyrimidine core structure. These molecules were synthesized and used to perform initial screening for the inhibition of purified bacterial phospholipase D, which is highly homologous to the human PLD1. Initially tested with the bacterial phospholipase D enzyme, then confirmed with the recombinant human PLD1 and PLD2 enzymes, the molecules presented here exhibited inhibition of phospholipase D activity (IC50) in the low-nanomolar to low-micromolar range with both monomeric substrate diC4PC and phospholipid vesicles and micelles. The data strongly indicate that these inhibitory molecules directly block enzyme/vesicle substrate binding. Preliminary activity studies using recombinant human phospholipase Ds in in vivo cell assays measuring both transphosphatidylation and head-group cleavage indicate inhibition in the mid- to low-nanomolar range for these potent inhibitory novel molecules in a physiological environment. This study reports synthesis of a new class of PLD inhibitors based on 1,3-disubstituted-4-amino-pyrazolopyrimidine core structure. These molecules exhibited inhibition of human recombinant PLD activity (IC 50) in the low-nanomolar to low-micromolar range with monomeric substrate diC4PC and phospholipid vesicles and micelles. Preliminary activity studies using recombinant human PLDs in in vivo cell assays measuring both transphosphatidylation and head-group cleavage indicates inhibition in the mid- to low-nanomolar range for these potent inhibitory novel molecules in a physiological environment.

PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE

Compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. [Fomula I]